We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · July 28, 2022

Nivolumab vs Cabozantinib in Second- or Third-Line Treatment of mRCC

Targeted oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Targeted oncology
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Target Oncol 2022 Jun 25;[EPub Ahead of Print], M Maruzzo, F Pierantoni, A Bortolami, D Palleschi, A Zivi, M Nicodemo, D Sartori, R De Vivo, F Zustovich, D Bimbatti, D Pastorelli, GD Vultaggio, M Soraru', M Ballestrin, C Modonesi, P Randisi, C Barile, G Perri, U Basso, V Zagonel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading